Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14664467 | 0.82 | DPP4 (0.66) | DPP4CYP3A4DPP8DPP9 | |
| SCHEMBL13563415 | 0.82 | DPP4 (0.66) | DPP4CYP3A4DPP8DPP9 | |
| SCHEMBL14648462 | 0.78 | DPP4 (0.48) | DPP4CYP3A4DPP8DPP9 | |
| SCHEMBL14136349 | 0.78 | DPP4 (0.48) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL23752173 | 0.78 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17131050 | 0.78 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| SCHEMBL7936708 | 0.78 | DPP4 (0.76) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL12518855 | 0.78 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL2742680 | 0.78 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| SCHEMBL15149531 | 0.78 | DPP4 (0.76) | DPP4CYP3A4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150511-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE US LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150511-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE US LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140235870-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235870-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2014-08-21 | — | — | US | disclosed |
| US-8748631-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE, LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748631-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE, LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130023671-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023671-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023671-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | DPP4, DPP3, DPP8 | DPP4 1/4885CYP3A4 38/4885DPP8 3/4885 |
| US-20140235870-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | DPP4, DPP3, DPP8 | DPP4 1/4885CYP3A4 38/4885DPP8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.